WHO Condemns Unethical Hepatitis B Birth Dose Vaccine Trial in Guinea-Bissau

The World Health Organization (WHO) has reaffirmed its strong support for the hepatitis B birth dose vaccine, responding to concerns raised about a proposed clinical trial in Guinea-Bissau that would withhold the vaccine from a control group. The trial, which has now been suspended by the Guinean government pending review, sparked debate over the ethics of withholding a proven, life-saving intervention, even in the context of research.

A Proven Intervention and a Critical Public Health Necessitate

Hepatitis B is a viral infection that attacks the liver, leading to both acute and chronic disease. The birth dose vaccine is a cornerstone of prevention, preventing mother-to-child transmission – the most common route of infection for newborns – with an efficacy rate of 70-95%. Globally, an estimated 254 million people were living with chronic hepatitis B infection in 2022, resulting in 1.1 million deaths, primarily from cirrhosis and liver cancer. WHO Fact Sheet on Hepatitis B

In Guinea-Bissau, the need for this vaccine is particularly acute. Over 12% of adults are estimated to be living with chronic hepatitis B and infection rates in children under five – around 2% in 2020 – are significantly higher than the global target of ≤0.1%. The country recently committed to adding the hepatitis B birth dose to its national immunization schedule, with implementation planned for 2028, a decision that underscores the vaccine’s recognized value.

Ethical Concerns Surrounding the Guinea-Bissau Trial

The proposed randomized controlled trial (RCT) in Guinea-Bissau raised significant ethical concerns for the WHO. The core issue centers on the principle of withholding a proven, effective intervention – the birth dose vaccine – from a portion of the study participants. The WHO argues that this practice is unethical when a clear benefit exists and foreseeable harm is likely.

Specifically, the WHO outlined several key concerns:

• Proven Benefit, Foreseeable Harm: The vaccine’s decades-long safety record and high efficacy imply that withholding it exposes newborns to the risk of chronic infection, cirrhosis, and liver cancer.
• Lack of Scientific Justification for a No-Treatment Arm: Placebo-controlled trials are generally reserved for situations where no effective treatment exists or when the trial design is essential to answer a critical question about efficacy or safety. Neither condition appears to be met in this case.
• Insufficient Evidence of Safety Concerns: The trial’s rationale appears to be based on hypothetical safety concerns without sufficient evidence to warrant exposing participants to risk.
• Potential for Bias: The single-blind, no-treatment-controlled design raises concerns about potential bias and the reliability of the study results.
• Ethical Implications of Resource Constraints: The WHO emphasizes that resource limitations cannot justify withholding proven care in a research setting.

The WHO’s position is rooted in established ethical principles for research involving human participants, which prioritize minimizing risk and maximizing benefit. The organization maintains that the trial, as publicly described, is inconsistent with these principles.

Understanding the Hepatitis B Birth Dose Vaccine

The hepatitis B birth dose vaccine works by stimulating the body’s immune system to produce antibodies against the hepatitis B virus. Administered within 24 hours of birth, it provides early protection, preventing the virus from establishing a chronic infection. WHO Position Paper on Hepatitis B Vaccines The vaccine is typically given as part of a series of doses, providing long-lasting, potentially lifelong, protection.

The global rollout of the hepatitis B birth dose vaccine has been remarkably successful. More than 115 countries have incorporated it into their national immunization schedules, significantly reducing the incidence of chronic hepatitis B infection and its associated complications.

What Comes Next: Supporting Guinea-Bissau and Strengthening Implementation

Following the suspension of the trial, Guinea-Bissau is undergoing a technical review to assess the study’s design and ethical considerations. The WHO has offered its support during this process and in accelerating the introduction of the birth dose vaccine into the national immunization program.

The WHO’s support will focus on several key areas:

• Ensuring timely birth dose delivery, including strategies for both facility and home births.
• Implementing antenatal screening for hepatitis B surface antigen (HBsAg) to identify pregnant women at risk of transmitting the virus to their newborns.
• Strengthening the cold chain and logistical infrastructure to ensure vaccine availability, and quality.
• Providing training for midwives and healthcare workers on vaccine administration and monitoring.
• Establishing robust monitoring systems to track vaccine coverage, identify potential adverse events, and continuously improve program effectiveness.

The WHO remains committed to working with national authorities, researchers, and partners to ensure that all newborns – in Guinea-Bissau and worldwide – receive timely, evidence-based protection against hepatitis B. This commitment extends to ensuring that all research conducted in this area adheres to the highest ethical and scientific standards. The organization emphasizes that the ultimate goal is to eliminate hepatitis B as a public health threat, and the birth dose vaccine is a critical tool in achieving that objective.

The situation in Guinea-Bissau serves as a stark reminder of the importance of ethical considerations in clinical research and the need to prioritize the well-being of vulnerable populations. It similarly highlights the critical role of vaccination in preventing infectious diseases and protecting public health. WHO on Hepatitis